MedTrace Logo

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

NCT07012486 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-06-10

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.
* Visit the clinic once every month for checkups and tests.

Conditions

  • Androgenetic Alopecia (AGA)

Interventions

DRUG

Oral DHA + Topical minoxidil 5%

DHA 20mg tid po plus daily topical minoxidil 5% for 180 days

DRUG

Topical Minoxidil 5%

Topical minoxidil 5% daily for 180 days

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Jingjing JIANG, MD, PhD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2026-05-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07012486 on ClinicalTrials.gov